Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Litigation Victory with Jury's Decision
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
Puma Biotech's Nerlynx remains a dud. Will a breast cancer expansion turn things around? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology
